Ownership history in ORBIMED ADVISORS LLC Β· 5 quarters on record
This page tracks every 13F SEC filing in which ORBIMED ADVISORS LLC reported a position in UPSTREAM BIO INC (UPB). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π ORBIMED ADVISORS LLC outperformed the S&P 500 by +115.0% annually on this UPB position. Average cost basis: $16.44. Maximum drawdown during holding period: β62.8%.
π₯ Exceptional β beat the S&P 500 by 115.0% per year on this position.
4 quarters analyzed
Best entry: $16.44 (2024 Q4) Β· Worst: $16.44 (2024 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
1 add Β· 0 trims. Bought during 0 of 1 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π ORBIMED ADVISORS LLC has been actively increasing its UPB allocation β a bullish signal from insiders.
Currently 3.16% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size